March 12 (Reuters) - POLYPEPTIDE GROUP AG PPGN.S :
* POLYPEPTIDE WITH RECORD REVENUE GROWTH OF 43% IN H2 2023
VERSUS
H1 2023; OPERATIONAL IMPROVEMENTS YIELDING INCREASED
PROFITABILITY AND CASH FLOW
* GROSS PROFIT IN 2023 WAS EUR 9.1 MILLION
* IT EXPECTS REVENUE GROWTH IN 2024 MID TO HIGH SINGLE-DIGIT
AT
CONSTANT CURRENCY RATES VERSUS 2023 WITH A POSITIVE EBITDA,
OPERATING AT A NET LOSS
* 2024 CAPITAL EXPENDITURE IS EXPECTED TO BE BETWEEN EUR 60
MILLION AND EUR 70 MILLION
* POLYPEPTIDE IS CURRENTLY PREPARING ITS MID-TERM OUTLOOK,
WHICH
IT PLANS TO PUBLISH ON 13 AUGUST 2024
* WITH THE NET LOSS REPORTED FOR 2023, THE GROUP WILL NOT BE
PROPOSING THE PAYMENT OF A DIVIDEND TO THE UPCOMING ANNUAL
GENERAL MEETING ON 10 APRIL 2024
Source text for Eikon: ID:nEQbjXmhca
Further company coverage: PPGN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))